Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-Dong, Songpa-gu, Seoul 138-736, South Korea.
Respir Med. 2013 Feb;107(2):292-7. doi: 10.1016/j.rmed.2012.10.021. Epub 2012 Nov 28.
We investigated the efficacy of rifabutin (RFB)-containing regimens for the treatment of RFB-susceptible, multidrug-resistant tuberculosis (MDR-TB).
From 146 patients diagnosed with MDR-TB between January 2006 and December 2009 at Asan Medical Center in South Korea, 31 patients (21.2%) were found to have RFB-susceptible MDR-TB. Of these 31 patients, 14 patients who had been treated with RFB for more than one month were included. Forty-two patients with RFB-resistant MDR-TB were selected as a control group, and the outcomes of both groups were retrospectively compared.
Of 14 patients with RFB-susceptible MDR-TB, the mean age was 44.4 years and the proportion of extensively drug-resistant TB (XDR-TB) was 35.7% (5/14). Baseline characteristics and the drug resistance pattern (except RFB) did not differ between the two groups. Treatment success was achieved in 12 (85.7%) patients in the RFB group: cure in 10 (71.4%) and treatment completion in two (14.3%). The treatment success rate was 52.4% (22/42) in the control group (p = 0.032). Treatment failure was more common in patients of the control group (40.5% vs. 14.3%; p = 0.106).
RFB is useful as an additional drug in the treatment of MDR-TB in patients with RFB-susceptible MDR-TB.
我们研究了含利福布汀（RFB）方案治疗利福平敏感、耐多药结核病（MDR-TB）的疗效。
从 2006 年 1 月至 2009 年 12 月在韩国峨山医学中心诊断为 MDR-TB 的 146 例患者中，发现 31 例（21.2%）患者具有利福平敏感的 MDR-TB。在这 31 例患者中，纳入了 14 例已接受利福平治疗超过 1 个月的患者。选择了 42 例利福平耐药 MDR-TB 患者作为对照组，并回顾性比较两组的结果。
在 14 例利福平敏感的 MDR-TB 患者中，平均年龄为 44.4 岁，广泛耐药结核病（XDR-TB）的比例为 35.7%（5/14）。两组的基线特征和耐药模式（除利福平外）均无差异。RFB 组的治疗成功率为 12 例（85.7%）：治愈 10 例（71.4%），完成治疗 2 例（14.3%）。对照组的治疗成功率为 52.4%（22/42）（p=0.032）。对照组的治疗失败更为常见（40.5%比 14.3%；p=0.106）。
利福布汀作为利福平敏感、耐多药结核病患者 MDR-TB 治疗的附加药物是有用的。
